Hamad Medical Corporation (HMC) has signed a Memorandum of Understanding (MoU) with the Qatar Biomedical Research Institute (QBRI), which will enable both entities to harness their combined medical research capabilities.
The agreement will also enhance an environment in which clinical discoveries will be translated into practical applications for the benefit of patients more quickly.
The MoU was signed by Hanan al-Kuwari, managing director, HMC and Dr Hilal Lashuel, executive director, QBRI. The new agreement will boost the resources of existing research teams studying health problems like diabetes, cancer, degenerative diseases and genetic disorders and pave the way for new research studies.
The MoU is expected to lead to further development of a skilled national healthcare workforce, providing numerous career and professional development opportunities for clinicians, researchers and faculty.
Dr al-Kuwari said the agreement emphasises the dedication of HMC and QBRI to improving patient outcomes through research and innovation. “HMC and QBRI have shown a commitment to fostering a culture of translational research and evidence-based care, which will ultimately lead to better overall patient outcomes across Qatar,” said al-Kuwari. Dr Lashuel said the initiative was demonstrative of the country’s strengthening scientific and medical research capabilities.
“This agreement is a catalyst for cutting-edge biomedical research, an essential element in today’s complex and evolving healthcare landscape. It reinforces Qatar’s position as a regional leader in biomedical research and scientific discovery,” said Dr Lashuel.
Scientists and executive management from QBRI and HMC after the signing of the MoU.
